Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06504368
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-18
Brief Title:
Safety Tolerability and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-Label Phase 1 Dose-Escalation Study to Evaluate the Safety Tolerability and Pharmacokinetics of Intravenous DCR-PDL1 in Adults With Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the safety tolerability and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors Participants will be enrolled in one of 4 ascending-dose cohorts Each treatment cycle will consist of multiple intravenous IV doses Dose escalation decisions will be based on data collected during the dose-limiting toxicity DLT period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None